|
|
Profile
|
Delegates :
Kiichiro Nabeta |
|
Incorporated :
January 8 , 1988 |
Paid in Capital :
10 Million yen |
Employees :
5 人 |
Address :
1-653-7-205 maruko-dori, nakahara-ku, kawasaki -city KANAGAWA
〒211-0006
|
TEL/FAX :
+81-44-435-6273 / +81-44-435-6273 |
URL：
https://www.technogrd.co.jp/ |
Attachment :
|
Mission/Background :
TECHNO GUARD Co.,Ltd. go on with the applied research of nano-technology from starting of nano-emulsion technique.
And now we have 6 nano-techniques and develop injections, ophthalmic solutions, tablets, suppositories, ointment.
By these nano-techniques, it is possible to make a good absorption of insoluble drug, a DDS formulation, a change of ADME.
Nano-API (API downsized in nano-scale) are used for ①bulk sales ②production of commercial formulation in customer’s factory ③production of commercial formulation in our factory.
|
|
Technology & Business
|
Nano-technique consists of ①nano-emulsion ②nano-solution ③nano-powder ④nano-non aqueous solution ⑤nano-semisolid ⑥nano-complex.
For the formulation containing nano-API, we choose optimum inactive pharmaceutical ingredient within the permissible range of the administration route according to JP, USP, EP.
The formulation is able to carry out not in vitro test, but on animal test (rat, pig etc.) and to estimate it’s characteristics.
New API, valuable active pharmaceutical ingredient is possible to investigate and make the formulation using a small amount of nano-API.
Now we develop formulations of anti-cancer drug, immuno-suppression drug etc.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Nano-API (API downsized in nano-scale) and Nano-formulation (containing nano-API)
|
Service/Marketing
|
Manufacture and sales nano-API and nano-formulation to pharmaceutical companies and trading companies
|
Make new nano-technique for all API.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We have 6 nano-techniques by developing new nano-technology.
We develop the formulation of new drug, NSAIDs, anti-cancer drug, cardiovascular drug and recently production schedule is going.
Our customer come from USA, Korea, India except JAPAN.
And our fundamental and developing research are supported by Kanagawa-pref., Kwasaki-city etc.
|
|
Alliance strategy
|
We handle with case by case
|
|
|